Xspray: Positive clinical data for HyNap-Sora

Research Note

2019-02-18

16:21

Xspray announced positive data from a phase I pilot study, comparing the bioavailability of HyNap-Sora to Nexavar/sorafenib.

MS

Mathias Spinnars

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.